[go: up one dir, main page]

MX2017008280A - Proceso para elaborar cenicriviroc y analogos relacionados. - Google Patents

Proceso para elaborar cenicriviroc y analogos relacionados.

Info

Publication number
MX2017008280A
MX2017008280A MX2017008280A MX2017008280A MX2017008280A MX 2017008280 A MX2017008280 A MX 2017008280A MX 2017008280 A MX2017008280 A MX 2017008280A MX 2017008280 A MX2017008280 A MX 2017008280A MX 2017008280 A MX2017008280 A MX 2017008280A
Authority
MX
Mexico
Prior art keywords
related analogs
cenicriviroc
making
making cenicriviroc
analogs
Prior art date
Application number
MX2017008280A
Other languages
English (en)
Inventor
Morra Nicholas
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MX2017008280A publication Critical patent/MX2017008280A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La descripción incluye compuestos de alta pureza que tienen antagonismo de CCR5 y/o CCR2, o una sal de estos, y procesos para sintetizarlos.
MX2017008280A 2014-12-23 2015-12-23 Proceso para elaborar cenicriviroc y analogos relacionados. MX2017008280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096286P 2014-12-23 2014-12-23
PCT/US2015/000289 WO2016105527A1 (en) 2014-12-23 2015-12-23 Process of making cenicriviroc and related analogs

Publications (1)

Publication Number Publication Date
MX2017008280A true MX2017008280A (es) 2017-12-07

Family

ID=56151264

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008280A MX2017008280A (es) 2014-12-23 2015-12-23 Proceso para elaborar cenicriviroc y analogos relacionados.

Country Status (14)

Country Link
US (2) US10526349B2 (es)
EP (1) EP3237424A4 (es)
JP (2) JP6716568B2 (es)
KR (1) KR20170097735A (es)
CN (2) CN112266392A (es)
AU (1) AU2015371250B2 (es)
BR (1) BR112017013130A2 (es)
CA (1) CA2971093A1 (es)
HK (1) HK1246299A1 (es)
IL (2) IL252985B (es)
MX (1) MX2017008280A (es)
RU (2) RU2020121461A (es)
SG (1) SG11201704837VA (es)
WO (1) WO2016105527A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
US10526349B2 (en) 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs
EP3471718A4 (en) 2016-06-21 2020-01-08 Tobira Therapeutics, Inc. PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF CENICRIVIROC
WO2018045043A1 (en) 2016-08-31 2018-03-08 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
WO2022065070A1 (ja) 2020-09-23 2022-03-31 株式会社クラレ 活性炭およびその活性炭を用いた水処理方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CN1151744A (zh) 1994-07-04 1997-06-11 武田药品工业株式会社 膦酸化合物及其制备和应用
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
CA2337307A1 (en) 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use
AU6870600A (en) * 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
EP2206702B1 (en) * 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
CA2479071A1 (en) * 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
CA2560298A1 (en) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Preparation with elevated content
CA2562388A1 (en) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
EP1825866A4 (en) 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
EA201390726A1 (ru) 2010-11-18 2014-06-30 Йельский Университет Бифункциональные молекулы с активностью, привлекающей антитела и ингибирующей проникновение вируса иммунодефицита человека
WO2014085808A1 (en) * 2012-11-30 2014-06-05 The Trustees Of The University Of Pennsylvania Methods for improving thymic recovery and preventing and treating graft versus host disease using ccr2 and ccr5 antagonists
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
MX2016012262A (es) 2014-03-21 2017-01-06 Tobira Therapeutics Inc Cenicriviroc para el tratamiento de fibrosis.
US10526349B2 (en) 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs
US20180110754A1 (en) 2015-02-10 2018-04-26 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis

Also Published As

Publication number Publication date
RU2017126215A3 (es) 2019-06-06
CA2971093A1 (en) 2016-06-30
CN112266392A (zh) 2021-01-26
WO2016105527A1 (en) 2016-06-30
US10526349B2 (en) 2020-01-07
JP2020158516A (ja) 2020-10-01
SG11201704837VA (en) 2017-07-28
HK1246299A1 (zh) 2018-09-07
EP3237424A4 (en) 2018-07-04
AU2015371250B2 (en) 2021-01-28
RU2725888C2 (ru) 2020-07-07
JP2018505148A (ja) 2018-02-22
EP3237424A1 (en) 2017-11-01
IL252985B (en) 2020-05-31
US20200216476A1 (en) 2020-07-09
IL252985A0 (en) 2017-08-31
AU2015371250A1 (en) 2017-07-06
JP6716568B2 (ja) 2020-07-01
CN107207538A (zh) 2017-09-26
RU2020121461A (ru) 2020-08-03
KR20170097735A (ko) 2017-08-28
BR112017013130A2 (pt) 2017-12-26
US20180327428A1 (en) 2018-11-15
RU2017126215A (ru) 2019-01-24
IL274142A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
PH12016502177A1 (en) Processes of preparing a jak1 inhibitor and new forms thereto
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
GR20140100479A (el) Συνθεση λιραγλουτιδης
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
MX2017014351A (es) Un proceso para la preparacion de epoxido de terpinoleno.
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
MX369501B (es) Proceso para la preparación de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno.
PT3630738T (pt) Processo para a produção de ozanimod
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
ZA201902125B (en) Process for the production of 2-alkylalkanol
PH12016501613B1 (en) Pyrazines modulators of gpr6
TW201613871A (en) Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene
MX2016017124A (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
SG10201908248PA (en) Processes for preparing fluoroketolides
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
MX2016009325A (es) Metodo para la preparacion de 1-alquil-3-difluorometil-5-fluor-1h- pirazol-4-carbaldehidos y 1-alquil-3-difluorometil-5-fluor-1h-pira zol-4-carboxilatos.
MY174200A (en) Process for reducing the chlorine content of organotetraphosphites
GB201607540D0 (en) Hydrcarbon production process
MX380240B (es) Preparación de piperidin-4-carbotioamida.
MX2018015871A (es) Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.
IN2014CH00444A (es)